Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
- Associated Conditions
- -
- Associated Therapies
- -
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 146
- Registration Number
- NCT04246489
- Locations
- 🇺🇸
The Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Karmanos Cancer Institute, Farmington Hills, Michigan, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04220775
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-08-21
- Target Recruit Count
- 70
- Registration Number
- NCT03840915
- Locations
- 🇺🇸
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
🇺🇸RCCA MD LLC - Bethesda, Bethesda, Maryland, United States
🇺🇸University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
- Conditions
- Anatomic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03620201
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT03579472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03524170
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT02723955
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.